AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Xencor to Present at Upcoming Investor Conferences

November 13, 2019

MONROVIA, Calif.--(BUSINESS WIRE)--Nov 13, 2019--

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced that company management will participate in two upcoming conferences:

Live webcasts of these presentations will be available under “Events & Presentations” in the Investors section of the Company’s website located at www.xencor.com. A replay of the events will be posted on the Xencor website approximately one hour after the live events and will be available for 30 days following the presentations.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases. Currently, 14 candidates engineered with Xencor’s XmAb ® technology are in clinical development internally and with partners. Xencor’s XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191113005714/en/

CONTACT: Charles Liles

626-737-8118

cliles@xencor.comMedia Contact

Jason I. Spark

Canale Communications

619-849-6005

jason@canalecomm.com

KEYWORD: CALIFORNIA NEW YORK EUROPE UNITED STATES UNITED KINGDOM NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY OTHER HEALTH HEALTH PHARMACEUTICAL ONCOLOGY

SOURCE: Xencor, Inc.

Copyright Business Wire 2019.

PUB: 11/13/2019 04:01 PM/DISC: 11/13/2019 04:01 PM

http://www.businesswire.com/news/home/20191113005714/en